Brille Brian J sold $12.1M of CAI

Brille Brian J (See Remarks) sold 400,000 shares of Caris Life Sciences, Inc. (CAI) at $30.33 ($12.13M total) on 2026-09-17.

Original reporting
SEC EDGAR · Brille Brian J
Published Sep 17, 2026, 10:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 10:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CAI
Bearish
medium confidence
Mentioned
$CAI
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CAIBearishLow
01

Why it matters

The disclosed sale reduces insider ownership and may be interpreted as a negative signal, prompting short interest.

02

Market read

Primary insider sale news; modest materiality but enough to affect short‑term price action.

03

What to watch

Potential upcoming clinical data releases or financing needs that prompted the insider to liquidate.

Relevance 7/10Novelty 7/10Timing: today

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

$CAIBearishMedium confidence
Context

Officer/director Brille Brian J sold 400,000 shares for $12.1M, reducing his stake to 230,303 shares.

Expected impact

Potential short-term dip of 2‑4% as market digests the sale.

Evidence & confidence

Insider sale of over $12M by a senior officer is material; investors often view such disposals as a bearish sign.

Market effects

Minimal impact on the broader biotech sector; the sale is company‑specific.

No significant regional effect; limited to investors tracking CAI.

Low global relevance; only affects CAI shareholders and biotech analysts.

Counterpoint

The sale could be a routine diversification rather than a lack of confidence, so price may hold.

Key entities

  • Caris Life Sciences, Inc.

    Biotech firm listed on Nasdaq under ticker CAI.

  • Brille Brian J

    Officer and director of Caris Life Sciences.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CAIMed

Caris Life Sciences Inc (CAI) Q3 2026 Earnings Call Highlights: Record Revenue, Sixth

Caris Life Sciences (CAI) reported Q3 2026 revenue growth, but faced negative free cash flow of $39.7M due to capital expenditures. Operating expenses rose $48.1M year-over-year, and full-year GAAP opex guidance was raised to ~$620M. New product launches without reimbursement may pressure margins. Q4 pharma R&D services revenue is expected to decline sequentially. The company is expanding its commercial team and expects positive free cash flow in Q4.

$CAIHigh

Caris Life (CAI) Q3 2026 Earnings Call Transcript

Caris Life (CAI) reported Q3 2026 earnings, highlighting 21% year-over-year clinical case growth and 27% revenue increase to $275M. The company launched new products, including Caris Assure for monitoring and plans to launch Caris Confirm for MRD in December. Caris Detect, their early-stage cancer detection test, is gaining market traction. The company maintained profitability with adjusted EBITDA of $44.4M and net income of $15.3M.

$CAIMed

TD Cowen raises Caris Life Sciences stock price target on pipeline

TD Cowen raised its price target for Caris Life Sciences (CAI) to $38 from $36, maintaining a Buy rating. The company reported Q3 sales beating expectations by 9%, with revenue up 85% year-over-year and a 70% gross margin. Despite this, shares fell 15% post-market due to an earnings miss. The stock has gained 65% since pre-Q2 levels, but InvestingPro suggests it may be overvalued.